Asset Details
Do you wish to reserve the book?
Upfront eBEACOPP chemotherapy without consolidation radiotherapy in early-stage unfavourable Hodgkin lymphoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Upfront eBEACOPP chemotherapy without consolidation radiotherapy in early-stage unfavourable Hodgkin lymphoma
Do you wish to request the book?
Upfront eBEACOPP chemotherapy without consolidation radiotherapy in early-stage unfavourable Hodgkin lymphoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Upfront eBEACOPP chemotherapy without consolidation radiotherapy in early-stage unfavourable Hodgkin lymphoma
2021
Overview
Attempts to omit radiotherapy in two previous phase 3 studies involving patients who had an early response after upfront treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) showed that the risk of treatment failure was higher in those who did not receive radiotherapy than in those who did, even though no difference in overall survival was observed between these two groups.4,5 In The Lancet Oncology, Peter Borchmann and colleagues6 present the results of the HD17 trial, which is the first study to show that radiotherapy can be safely omitted in patients who achieve a complete metabolic response after an intensified chemotherapy regimen consisting of two cycles of escalated doses of etoposide, cyclophosphamide, and doxorubicin, and regular doses of bleomycin, vincristine, procarbazine, and prednisone (eBEACOPP) plus two cycles of ABVD (2 + 2), without impairing disease control. Baseline PET was not mandatory in the HD17 study, but in routine practice, pretreatment PET could be valuable for accurately implementing the reduced tumour volume radiotherapy approach by targeting involved nodes and limiting the risk of uncertainty in the target volume delineation, which could otherwise have led to interobserver inconsistencies, and in some cases, delivery of an increased dose to non-target organs.7 This study6 provides additional evidence supporting the prognostic effect of interim PET, and the pivotal role of PET in guiding the treatment of patients with Hodgkin lymphoma, including those given upfront eBEACOPP.8 Interim PET interpretation criteria are important for optimising patient management. [...]omitting involved-node radiotherapy in patients with a Deauville score of 3 or higher after induction therapy should be tested further before extending this approach to these patients in routine clinical practice.
Publisher
Elsevier Ltd,Elsevier Limited
